Today's Trend
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is receiving mixed analyst signals. Bullish ratings and a higher price target are supporting investor sentiment, while reduced earnings forecasts and expectations for limited near-term revenue growth remain headwinds.
- Truist raises price target: Truist Financial increased its target for Viridian from $38 to $39 and maintained a “Buy” rating, implying substantial potential upside based on the referenced share price. Benzinga
- LifeSci Capital issues a Buy rating: The favorable recommendation adds to the positive analyst coverage surrounding Viridian and may reinforce confidence in the company’s pipeline and longer-term commercial prospects. LifeSci Capital Buy Rating
- Analyst expectations remain focused on future profitability: Viridian is still expected to report substantial losses in 2026, with the broader consensus calling for a full-year loss of $3.87 per share. HC Wainwright’s estimates imply a possible return to profitability by 2030, but the timeline remains distant.
- RBC sees minimal second-half revenue growth: RBC Capital Markets reportedly expects limited revenue expansion during the second half of 2026, a concern for investors seeking evidence of accelerating commercialization. RBC Revenue Growth Outlook
- HC Wainwright cuts multiyear EPS forecasts: The firm reduced its loss estimates for the third and fourth quarters of 2026 and lowered forecasts for fiscal 2027 through 2029. Its 2030 earnings estimate was also cut from $0.90 to $0.40 per share, indicating slower anticipated progress toward profitability. HC Wainwright Earnings Estimates
Overall, VRDN’s recent strength appears to be supported by bullish analyst ratings and price-target upgrades, although weaker revenue expectations and downward revisions to earnings forecasts could limit gains and increase volatility.